BioCatalyst

WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously, Sorafenib 400 mg PO, BID — catalyst calendar

1 verified catalyst event(s) referencing WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously, Sorafenib 400 mg PO, BID, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
Phase 2 Study of WGI-0301 for Advanced HCC
Phase 2 · Advanced Hepatocellular Carcinoma (HCC)
 Zhejiang Haichang Biotech Co., Ltd WGI-0301 at MTD/RP2D dose IV infusion, Q ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.